

SAN FRANCISCO EMERGENCY MEDICAL SERVICES AGENCY

Effective: 09/01/06
Supersedes: 02/01/05

Protocol: P-041

PEDIATRIC ALTERED MENTAL STATUS

SUBJECTIVE FINDINGS

- Surroundings: pill bottles, syringes, insulin, alcohol containers, etc.
- Change in mental status: baseline status, onset and progression of altered state, antecedent symptoms such as fever, respiratory distress, headache, seizures, confusion, trauma, etc.
- **Medical history: psychiatric and medical problems, medications, and allergies.**
- **Hx of Diabetes Mellitus and type of medication (oral vs. insulin).**

OBJECTIVE FINDINGS

- Appearance: "TICLS" (tone, interactiveness, consolability, look/gaze, speech/cry).
- LOC and neurological assessment (remember to gauge neurologic functioning by appropriate response for age; parents and guardians are good sources of information as to whether the infant or child's reaction to verbal or tactile stimuli is baseline).
- Signs of trauma.
- Pupil size, equality and reactivity.
- Medical information bracelets or medallions.
- Blood glucose level.
- Vital signs and temperature.

KNOWN OR SUSPECTED HYPOGLYCEMIA	
BLS Treatment	ALS Treatment
<ul style="list-style-type: none">• Glucose paste or other oral Glucose administration if patient is able to maintain their airway and follow commands.• Routine Medical Care.	<ul style="list-style-type: none">• IV or IO of NS.• Dextrose:<ul style="list-style-type: none">*Neonates < 1 month: D10W, 1-2 ml/kg IVP or IO*Child 1 month to 2 years: D25W, 2 ml/kg IVP or IO*Child > 2 years: D50W, 1 ml/kg IVP or IO <p>If no IV access</p> <ul style="list-style-type: none">• Glucagon: 0.1 mg/kg IM (max. dose 1 mg).

SAN FRANCISCO EMERGENCY MEDICAL SERVICES AGENCY

Effective: 09/01/06
Supersedes: 02/01/05

Protocol: P-041

UNKNOWN CAUSE	
BLS Treatment	ALS Treatment
<ul style="list-style-type: none"> Field primary survey, ensure protective position or need for C- Spine precautions. Ensure ABC's, oxygenation, ventilation, and suction prn. Oxygen by blow-by, mask, or high flow prn, assist ventilations with BVM prn. Routine Medical Care. 	<p>IV or IO of NS.</p> <p>Naloxone:</p> <ul style="list-style-type: none"> <u>AVOID Naloxone</u> in the neonate. <u>Infant or Child up to 5 years old (< 20 kg):</u> 0.1 mg/kg IVP, IM or IO . <u>Children 5 – 10 years old (> 20 kg):</u> 2 mg IN via MAD (preferred) See PRECAUTIONS AND COMMENTS) or IVP, IM or IO. Repeat prn. <u>Children > 10 years old:</u> 2 mg IN via MAD (preferred) See PRECAUTIONS AND COMMENTS) or IVP, IM or IO. <p>If rapid blood glucose test shows glucose < 60 mg/dl for child; < 40 mg/dl for newborn. (see PRECAUTIONS AND COMMENTS)</p> <p>Dextrose:</p> <ul style="list-style-type: none"> <u>*Neonates (< 1 month):</u> D10W, 1-2 ml/kg IVP or IO, <u>*Child 1 month to 2 years:</u> D25W, 2 ml/kg IVP or IO. <u>*Child > 2 years:</u> D50W, 1 ml/kg IVP or IO. <p>If no IV access, Glucagon 0.1 mg/kg IM (max dose 1 mg)</p> <ul style="list-style-type: none"> If hypotensive, administer fluid bolus 20 ml/kg.

DOCUMENTATION

Correct doses of medications administered if indicated.

Blood glucose documented.

Glucose given if BG is < 60 mg/dl.

Oxygen administered.

PRECAUTIONS AND COMMENTS

- Blood glucose: consider **Dextrose** for any child with an altered level of consciousness and blood glucose test of < 80 mg/dl; and consider not treating a normal child with blood glucose > 60 mg/dl.
- D25W** is half strength **D50W**. Mix 1ml of D50W with each 1 ml of NS.
- D10W** is made by mixing 1 ml of **D50W** with 4 ml of NS.
- Be attentive for excessive oral secretions, vomiting, and inadequate tidal volume.
- Consider suspected child maltreatment and/or occult head trauma in patients with seizures and utilize pediatric trauma treatment protocols. Be aware of child maltreatment reporting requirements in these cases.

SAN FRANCISCO EMERGENCY MEDICAL SERVICES AGENCY

Effective: 09/01/06
Supersedes: 02/01/05

Protocol: P-041

INTRANASAL (IN) MUCOLSAL ADMINISTRATION OF NALOXONE

Use of Mucosal Atomizing Device (MAD):

- Patient should be in a recumbent or supine position. If the patient is sitting, compress the nares after administration.
- Draw up 2 mg of **Naloxone** into a 3 ml syringe.
- Expel any air within the syringe.
- Attach the MAD to the syringe and confirm that it is secured firmly to the syringe.
- Insert syringe with the MAD attached into nares.
- Briskly compress the syringe plunger to expel and atomize the medication.

Contraindications to intranasal administration include:

- Facial trauma.
- Epistaxis.
- Nasal congestion or discharge.
- Any recognized nasal mucosal abnormality.

Note:

- No more than 1 ml of medication should be administered per nostril.
 - No more than 0.5 ml of medication should be administered per nostril for children < **10 years.**
-